Orforglipron side effects include gastrointestinal reactions, headache and hair loss, but the Foundayo safety information also includes warnings that deserve separate attention. These cover thyroid C-cell tumours, pancreatitis, dehydration and acute kidney injury, hypoglycaemia, gallbladder disease, diabetic retinopathy and aspiration during anaesthesia.
According to the supplied Lilly announcement, the FDA approved Foundayo, the brand name for orforglipron, on 1 April 2026. It is an oral, non-peptide, small-molecule GLP-1 receptor agonist. Its tablet formulation does not remove the need to understand its warnings, contraindications and potential interactions.
This article separates reported adverse effects from more serious label warnings and explains what the available trial figures mean. It is informational, not a guide to dosing, treatment decisions or managing symptoms.
What Side Effects Does the Foundayo Safety Information Include?
The supplied approved-label safety summary identifies gastrointestinal adverse effects, headache and hair loss, alongside several potentially serious risks. These should not all be interpreted in the same way: a reported side effect, a warning and a contraindication have different meanings.
- Reported adverse effects: Gastrointestinal reactions, headache and hair loss.
- Thyroid warning and contraindications: Thyroid C-cell tumour risk, with use contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- Other important warnings: Pancreatitis, severe gastrointestinal disease, dehydration and acute kidney injury, hypoglycaemia, gallbladder disease, diabetic retinopathy and aspiration under anaesthesia.
- Contraceptive interaction: Oral contraceptives may be less effective.
This is an overview of the supplied safety information, not a replacement for the complete prescribing information. The presence of a warning does not mean every person will experience that problem. Equally, an adverse effect should not be dismissed simply because it is not among the most frequently discussed reactions.
Gastrointestinal Side Effects of Orforglipron
Gastrointestinal adverse effects were the main tolerability finding highlighted in the supplied summary of ATTAIN-1. In that trial, adverse events were mostly mild-to-moderate gastrointestinal events.
That description provides useful context, but it has limits. Mostly mild-to-moderate does not mean that all reactions were mild, that everyone tolerated treatment, or that serious gastrointestinal concerns can be ignored. The approved-label safety information also addresses severe gastrointestinal disease.
Why the Severity Description Matters
Trial reports distinguish the severity of an event from whether someone continued treatment. A reaction described as mild or moderate may still affect tolerability. Conversely, a study-wide summary cannot predict how a particular individual will respond.
The supplied reference does not provide a complete symptom-by-symptom frequency table. It would therefore be misleading to assign percentages to individual gastrointestinal symptoms or present an unsupported ranking of them.
The Thyroid C-Cell Tumour Warning
The thyroid C-cell tumour warning is a central part of the Foundayo safety information. It should not be treated as a minor footnote beneath a list of digestive side effects.
Foundayo is contraindicated in people with:
- A personal history of medullary thyroid carcinoma.
- A family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia syndrome type 2, also called MEN2.
A contraindication is different from an ordinary precaution: it identifies a circumstance in which the medicine should not be used. Medullary thyroid carcinoma is a specific thyroid cancer, and MEN2 is a hereditary endocrine tumour syndrome. These terms should not be blurred into a general reference to thyroid problems.
The supplied material does not establish a human thyroid cancer incidence figure. No numerical estimate of that risk can responsibly be drawn from the information provided here.
Other Serious Warnings Explained
Pancreatitis
Pancreatitis, meaning inflammation of the pancreas, appears in the approved-label safety summary. It belongs in a discussion of serious warnings rather than being grouped casually with routine digestive discomfort. The supplied reference does not provide an incidence rate, so its frequency cannot be quantified here.
Severe Gastrointestinal Disease
The safety information includes a warning concerning severe gastrointestinal disease. This is distinct from the broader observation that gastrointestinal events in ATTAIN-1 were mostly mild to moderate. A general trial summary does not cancel a condition-specific warning in the prescribing information.
Dehydration and Acute Kidney Injury
Dehydration and acute kidney injury are also identified safety concerns. Acute kidney injury means a sudden decline in kidney function. Their inclusion shows why the safety discussion extends beyond digestive tolerability to potentially significant effects on overall health.
Hypoglycaemia
Hypoglycaemia means low blood glucose. The supplied safety information particularly highlights this risk when orforglipron is used with insulin or sulfonylureas. The combination of medicines matters: a safety profile cannot be understood fully by considering Foundayo in isolation.
Gallbladder Disease and Diabetic Retinopathy
Gallbladder disease and diabetic retinopathy are listed among the important safety concerns. Diabetic retinopathy is damage to the retina associated with diabetes. These are separate warnings involving different organ systems, not alternative names for gastrointestinal side effects.
Aspiration During Anaesthesia
The safety information also includes aspiration under anaesthesia. Aspiration refers to material entering the airways or lungs. This warning makes the procedural setting part of the safety picture, rather than limiting attention to symptoms experienced during everyday activities.
Headache and Hair Loss
Headache and hair loss are also included in the supplied Foundayo safety summary. They deserve mention because discussions of GLP-1 medicines often focus almost exclusively on gastrointestinal effects.
However, the supplied material does not give their frequency, severity, timing or duration. It also does not establish a mechanism for hair loss. Claims that either effect is inevitable, temporary or explained by one particular cause would go beyond the available reference.
Can Orforglipron Affect Oral Contraceptives?
The supplied safety information states that oral contraceptives may be less effective. This is a potential interaction, not simply another symptom on a side-effect list.
That distinction matters because an interaction may affect another medicine without producing an obvious adverse sensation. The reference supplied here does not provide the full contraceptive instructions from the prescribing information. This article therefore does not specify alternative methods, timing or other management steps.
What ATTAIN-1 Shows About Treatment Discontinuation
The supplied reference identifies ATTAIN-1, published in the New England Journal of Medicine as NEJMoa2511774, as a trial involving 3,127 participants. Discontinuation because of adverse events occurred in:
- 5.3% of participants in one orforglipron group.
- 7.9% in another orforglipron group.
- 10.3% in another orforglipron group.
- 2.7% in the placebo group.
These figures describe stopping treatment because of adverse events. They do not represent the percentage experiencing any side effect, the rate of serious adverse events or the likelihood of a particular symptom.
The distinction is important for interpreting searches about orforglipron side effects. Trial tolerability data add context, but they do not replace the contraindications and warnings in the approved prescribing information.
The Bottom Line on Foundayo Side Effects
The Foundayo safety picture includes both tolerability concerns and potentially serious risks. Gastrointestinal adverse events were prominent in ATTAIN-1, while headache and hair loss also appear in the supplied safety summary. The thyroid C-cell tumour warning and the contraindications involving medullary thyroid carcinoma and MEN2 require particular attention.
A balanced reading keeps reported symptoms, serious warnings, medicine interactions and trial discontinuation rates separate. None of those categories alone tells the whole story, and the complete prescribing information remains the primary reference for the approved safety details.
